[1]田雪琪a,宋佳俊a,顾怿丰a,等.基于血液生物标志物的外周免疫评分及在非小细胞肺癌应用中的研究进展[J].现代检验医学杂志,2024,39(01):192-198.[doi:10.3969/j.issn.1671-7414.2024.01.036]
 TIAN Xueqia,SONG Jiajuna,GU Yifenga,et al.Research Progress of Peripheral Immune Score Based on Blood Biomarkers and Its Application in Non-small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2024,39(01):192-198.[doi:10.3969/j.issn.1671-7414.2024.01.036]
点击复制

基于血液生物标志物的外周免疫评分及在非小细胞肺癌应用中的研究进展()
分享到:

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年01期
页码:
192-198
栏目:
综述
出版日期:
2024-01-15

文章信息/Info

Title:
Research Progress of Peripheral Immune Score Based on Blood Biomarkers and Its Application in Non-small Cell Lung Cancer
文章编号:
1671-7414(2024)01-192-07
作者:
田雪琪a宋佳俊a顾怿丰a吴冠锦a焦丽静ab许 玲ab
(上海中医药大学附属岳阳中西医结合医院a. 肿瘤一科;b. 中西医结合肿瘤转化研究所,上海 200437)
Author(s):
TIAN Xueqia SONG Jiajuna GU Yifenga WU Guanjina JIAO Lijingab XU Lingab
(a. Department I of Oncology; b. Institute of Tumor Transformation of Integrated Traditional Chinese and Western Medicine, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China)
关键词:
非小细胞肺癌外周免疫评分预测模型
分类号:
R734.2;R730.43
DOI:
10.3969/j.issn.1671-7414.2024.01.036
文献标志码:
A
摘要:
肺癌是目前中国人群中发病率和死亡率最高的恶性肿瘤,美国癌症联合委员会(American Joint Committee onCancer,AJCC)和国际抗癌联盟(International Union Against Cancer,UICC)制定的肿瘤淋巴结转移分类(tumor nodemetastasiss,TNM)分期是判断非小细胞肺癌(non-small cell lung cancer,NSCLC)分期的常用标准,但其在判断预后方面仍存在局限性。基于外周血生物标志物的免疫评分被证明在NSCLC 患者中具有预测药物疗效和患者预后的能力,且具有取样方便、实时检测等优势,被广泛开发、验证,但临床上对外周免疫评分的应用尚未普及。因此,该文总结、质量评价6 项外周免疫评分,并就外周免疫评分在NSCLC中的应用进行述评,以期总结目前外周免疫评分的价值和不足,为今后的研究和应用提供参考。
Abstract:
Lung cancer is the malignant tumor with the highest incidence and mortality among the Chinese. Tumor node metastasis (TNM) staging established by the American Joint Committee on Cancer (AJCC) and International Union Against Cancer (UICC) is a commonly used criterion, but it still has limitations in judging the prognosis of non-small cell lung cancer (NSCLC)patients. With the advantages of real-time and convenient sampling, the immune score based on peripheral blood biomarkers have the ability to predict prognosis and efficacy of NSCLC patients, which have been developed and validated in clinical studies. However, clinical impleruentation of peripheral immune scores is still not widely in NSCLC patients. Therefore, this study introduces and evaluates the 6 peripheral immune scores and reviews the reseach progress of them in the treatment of NSCLC.

参考文献/References:

[1] XIA Changfa, DONG Xuesi, LI He, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chinese Medical Journal, 2022, 135(5): 584-590.
[2] SHUKUYA T, CARBONE D P. Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer[J]. Journal of Thoracic Oncology, 2016, 11(7): 976-988.
[3] LEE J S, RUPPIN E. Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1[J]. JAMA Oncology, 2019, 5(11): 1614-1618.
[4] GALON J, PAG?S F, MARINCOLA F M, et al. Cancer classification using the immunoscore: a worldwide task force [J]. Journal of Translational Medicine, 2012, 10: 205.
[5] MAZZASCHI G, MINARI R, ZECCA A, et al. Soluble PD-L1 and circulating CD8+PD-1+ and NK cells enclose a prognostic and predictive immune effector score in immunotherapy treated NSCLC patients [J].Lung Cancer, 2020, 148: 1-11.
[6] GALON J, COSTES A, SANCHEZ-CABO F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome[J].Science, 2006, 313(5795): 1960-1964.
[7] FRIDMAN W H, PAG?S F, SAUT?S-FRIDMAN C, et al. The immune contexture in human tumours: impact on clinical outcome[J]. Nature Reviews Cancer, 2012, 12(4): 298-306.
[8] MAZZASCHI G, FACCHINETTI F, MISSALE G, et al. The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC [J]. Lung Cancer, 2019, 127: 153-163.
[9] INOMATA M, KADO T, OKAZAWA S, et al. Peripheral pd1-positive cd4 t-lymphocyte count can predict progression-free survival in patients with nonsmall cell lung cancer receiving immune checkpoint inhibitor[J]. Anticancer Research, 2019, 39(12): 6887-6893.
[10] TANIZAKI J, HARATANI K, HAYASHI H, et al. Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab[J]. Journal of Thoracic Oncology, 2018, 13(1): 97-105.
[11] ZHANG Zhibo, LI Ye, YAN Xiang, et al. Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis[J].Cancer Medicine, 2019, 8(4): 1467-1473.
[12] 夏经纬, 陈羽中, 温少迪, 等. 外周血炎症指标作为预测性指标在晚期非小细胞肺癌免疫治疗中的应用[J]. 中国肺癌杂志, 2021, 24(9): 632-645. XIA Jingwei, CHEN Yuzhong, WEN Shaodi, et al. Peripheral blood inflammation indicators as predictive indicators in immunotherapy of advanced non-small cell lung cancer [J]. Chinese Journal of Lung Cancer, 2021, 24(9): 632-645.
[13] ARKENAU H T, OLMOS D, ANG J E, et al. 90-days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial?[J]. European Journal of Cancer, 2008, 44(11): 1536-1540.
[14] ARKENAU H T, OLMOS D, ANG J E, et al. Clinical outcome and prognosic factors for patients treated within the context of a phase I study: the Royal Marsden Hosptal experience[J]. British Journal of Cancer, 2008, 98(6): 1029-1033.
[15] LIU J, WU Q, WU S, et al. Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs)[J]. Clinical and Translational Oncology, 2021, 23(9):1782-1793.
[16] ARKENAU H T, BARRIUSO J, OLMOS D, et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials[J]. Journal of Clinical Oncology, 2009, 27(16): 2692-2696.
[17] MASSARD C, BORGET I, LE DELEY M C, et al. Prognostic value of circulating VEGFR2+ bone marrowderived progenitor cells in patients with advanced cancer[J]. European Journal of Cancer, 2012, 48(9): 1354-1362.
[18] MARTINI D J, LIU Yuan, SHABTO J M, et al. Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials[J].Investigational New Drugs, 2019, 37(6): 1198-1206.
[19] BIGOT F, CASTANON E, BALDINI C, et al. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: the Gustave Roussy immune score (GRIm-Score) [J]. European Journal of Cancer, 2017, 84: 212-218.
[20] MINAMI S, IHARA S, IKUTA S, et al. Gustave roussy immune score and royal marsden hospital prognostic score are biomarkers of immune-checkpoint inhibitor for non-small cell lung cancer[J]. World Journal of Oncology, 2019, 10(2): 90-100.
[21] LENCI E, CANTINI L, PECCI F, et al. The gustave roussy immune (GRIm)-score variation is an early-ontreatment biomarker of outcome in advanced non-small cell lung cancer (NSCLC) patients treated with firstline pembrolizumab[J]. Journal of Clinical Medicine, 2021, 10(5): 1005.
[22] MINAMI S, IHARA S, KOMUTA K. Gustave roussy immune score is a prognostic factor for chemotherapynaive pulmonary adenocarcinoma with wild-type epidermal growth factor receptor[J]. World Journal of Oncology, 2019, 10(1): 55-61.
[23] LI Shuangjiang, ZHAO Liang, WANG Hongyu, et al. Gustave roussy immune score based on a three-category risk assessment scale serves as a novel and effective prognostic indicator for surgically resectable earlystage non-small-cell lung cancer: a propensity score matching retrospective cohort study [J]. International Journal of Surgery, 2020, 84: 25-40.
[24] MINAMI S, IHARA S, KOMUTA K. Gustave roussy immune score and royal marsden hospital prognostic score are prognostic markers for extensive disease of small cell lung cancer[J]. World Journal of Oncology, 2020, 11(3): 98-105.
[25] ZHANG Yi, CHEN Bo, WANG Lijuan, et al. Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: a metaanalysis[J]. Medicine, 2019, 98(3): e13788.
[26] FENG Jifeng, WANG Liang, YANG Xun, et al. Gustave roussy immune score (GRIm-score) is a prognostic marker in patients with resectable esophageal squamous cell carcinoma[J]. Journal of Cancer, 2020, 11(6): 1334-1340.
[27] TIAN Shan, CAO Yinghao, DUAN Yanran, et al. Gustave roussy immune score as a novel prognostic scoring system for colorectal cancer patients: a propensity score matching analysis[J]. Frontiers in Oncology, 2021, 11: 737283.
[28] HU Bo, YANG Xinrong, XU Yang, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma[J]. Clinical Cancer Research, 2014, 20(23): 6212-6222.
[29] JOMRICH G, GRUBER E S, WINKLER D, et al. Systemic immune-inflammation index (SII) predicts poor survival in pancreatic cancer patients undergoing resection[J]. Journal of Gastrointestinal Surgery, 2020, 24(3): 610-618.
[30] TERASAKI F, SUGIURA T, OKAMURA Y, et al. Systemic immune-inflammation index as a prognostic marker for distal cholangiocarcinoma[J]. Surgery Today, 2021, 51(10): 1602-1609.
[31] LI Wen, MA Guangzhi, DENG Yunfu, et al. Systemic immune-inflammation index is a prognostic factor for breast cancer patients after curative resection [J].Frontiers in Oncology, 2021, 11: 570208.
[32] XU Jianjun, HU Shaobo, LI Suzhen, et al. Systemic immune-inflammation index predicts postoperative acute kidney injury in hepatocellular carcinoma patients after hepatectomy[J]. Medicine, 2021, 100(14): e25335.
[33] FU Fangqiu, DENG Chaoqiang, WEN Zhexu, et al. Systemic immune-inflammation index is a stagedependent prognostic factor in patients with operable non-small cell lung cancer[J]. Translational Lung Cancer Research, 2021, 10(7): 3144-3154.
[34] YEKED?Z E, DOGAN ?, KAYA D M, et al. Systemic immune-inflammation index as a prognostic marker of late recurrence in operable gastric cancer: a dual-center study[J]. Journal of Gastrointestinal Cancer, 2022, 53(4): 870-879.
[35] JAFRI S H, SHI Runhua, MILLS G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review[J].BMC Cancer, 2013, 13: 158.
[36] BACHA S, SGHAIER A, HABIBECH S, et al. Advanced lung cancer inflammation index: a prognostic score in patients with metastatic non-small cell lung cancer[J]. La Tunisie Medicale, 2017, 95(11): 976-981.
[37] LU Ping, MA Yifei, KAI Jindan, et al. A low advanced lung cancer inflammation index predicts a poor prognosis in patients with metastatic non-small cell lung cancer [J]. Frontiers in Molecular Biosciences, 2021, 8: 784667.
[38] HUA Xin, CHEN Jing, WU Ying, et al. Prognostic role of the advanced lung cancer inflammation index in cancer patients: a meta-analysis[J]. World Journal of Surgical Oncology, 2019, 17(1): 177.
[39] ALDEA M, BENITEZ J C, MEZQUITA L. The lung immune prognostic index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients[J]. Translational Lung Cancer Research, 2020, 9(4): 967-970.
[40] HUANG Litang, HAN Hedong, ZHOU Li, et al. Evaluation of the lung immune prognostic index in nonsmall cell lung cancer patients treated with systemic therapy: a retrospective study and meta-analysis[J].Frontiers in Oncology, 2021, 11: 670230.
[41] PARK W, KWON D, SARAVIA D, et al. Developing a predictive model for clinical outcomes of advanced non-small cell lung cancer patients treated with nivolumab[J]. Clinical Lung Cancer, 2018, 19(3): 280-288, e4.
[42] PARK W, MEZQUITA L, OKABE N, et al. Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer[J].British Journal of Cancer, 2020, 122(3): 340-347.
[43] 陈香萍, 张奕, 庄一渝, 等. PROBAST: 诊断或预后多因素预测模型研究偏倚风险的评估工具[J]. 中国循证医学杂志, 2020, 20(6): 737-744. CHEN Xiangping, ZHANG Yi, ZHUANG Yiyu, et al. PROBAST: a tool for assessing risk of bias in the study of diagnostic or prognostic multi-factorial predictive models[J]. Chinese Journal of Evidence-Based medicine, 2020, 20(6): 737-744.
[44] LIU Jingjing, LI Shuang, ZHANG Shuang, et al. Systemic immune-inflammation index, neutrophilto-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab[J].Journal of Clinical Laboratory Analysis, 2019, 33(8): e22964.
[45] SHIROYAMA T, SUZUKI H, TAMIYA M, et al. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumabtreated patients with advanced non-small cell lung cancer[J]. Cancer Medicine, 2018, 7(1): 13-20.
[46] RUIZ-BA?OBRE J, ARESES-MANRIQUE M C, MOSQUERA-MART?NEZ J, et al. Evaluation of the lung immune prognostic index in advanced nonsmall cell lung cancer patients under nivolumab monotherapy[J]. Translational Lung Cancer Research, 2019, 8(6): 1078-1085.
[47] WEST H, MCCLEOD M, HUSSEIN M, et al. Atezolizumab in combination with carboplatin plus nabpaclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic nonsquamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial[J].Lancet Oncology, 2019, 20(7): 924-937.
[48] YUAN Zhijun, WENG Shanshan, YE Chenyang, et al. CSCO guidelines for colorectal cancer version 2022: Updates and discussions[J]. Chinese Journal of Cancer Research, 2022, 34(2): 67-70.
[49] MOUNTZIOS G, SAMANTAS E, SENGHAS K, et al. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer [J].ESMO Open, 2021, 6(5): 100254.
[50] HOPKINS A M, KICHENADASSE G, ABUHELWA A Y, et al. Value of the lung immune prognostic index in patients with non-small cell lung cancer initiating first-line atezolizumab combination therapy: subgroup analysis of the IMPOWER150 trial[J]. Cancers, 2021, 13(5): 1176.
[51] WANG Wenxian, HUANG Zhangzhou, YU Zongyang, et al. Prognostic value of the lung immune prognostic index may differ in patients treated with immune checkpoint inhibitor monotherapy or combined with chemotherapy for non-small cell lung cancer[J].Frontiers in Oncology, 2020, 10: 572853.
[52] DENG Chao, ZHANG Na, WANG Yapeng, et al. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs[J]. Medicine, 2019, 98(33): e16875.
[53] CHANTHARAKHIT C, SUJARITVANICHPONG N. Prognostic impact of the advanced lung cancer inflammation index (ALI) in metastatic non-small cell lung cancer treated with first line chemotherapy[J].Asian Pacific Journal of Cancer Prevention, 2021, 22(4): 1149-1156.
[54] HAN Zhaohui, HU Zhonghui, ZHAO Qingtao, et al. The advanced lung cancer inflammation index predicts outcomes of patients with non-small cell lung cancer following video-assisted thoracic surgery[J]. Journal of International Medical Research, 2021, 49(12): 3000605211062442.
[55] WANG Jianyang, HUI Zhouguang, MEN Yu, et al. Systemic inflammation-immune status predicts survival in stage III-N2 non-small cell lung cancer[J]. Annals of Thoracic Surgery, 2019, 108(6): 1701-1709.
[56] GAO Yongyin, ZHANG Hongdian, LI Yue, et al. Preoperative increased systemic immune-inflammation index predicts poor prognosis in patients with operable non-small cell lung cancer [J]. Clinica Chimica Acta, 2018, 484: 272-277.
[57] TOMITA M, AYABE T, MAEDA R, et al. Comparison of inflammation-based prognostic scores in patients undergoing curative resection for non-small cell lung cancer[J]. World Journal of Oncology, 2018, 9(3): 85-90.
[58] KAZANDJIAN D, GONG Yutao, KEEGAN P, et al. Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small cell lung cancer[J]. JAMA Oncology, 2019, 5(10): 1481-1485.
[59] 张玲玲, 张小霞, 於潇潇, 等. 非小细胞肺癌患者血浆miR-520f, miR-143-3p 表达与病理特征和预后的相关性研究[J]. 现代检验医学杂志, 2022, 37(3): 69-72, 78. ZHANG Lingling, ZHANG Xiaoxia, YU Xiaoxiao, et al. Correlation study on plasma miR-520f and miR-143-3p expression with pathological features and prognosis in patients with non-small cell lung cancer [J]. Journal of Modern Laboratory Medicine, 2022, 37(3): 69-72, 78.
[60] 刘延梅, 马少君, 马庆, 等. 非小细胞肺癌患者组织EGFR 基因突变状况及预后分析[J]. 现代检验医学杂志, 2019, 34(1): 22-25. LIU Yanmei, MA Shaojun, MA Qing, et al. Analysis of the status and outcome of epidermal growth factor receptor mutations in non-small cell lung cancer patients [J]. Journal of Modern Laboratory Medicine, 2019, 34(1): 22-25.
[61] MAZZASCHI G, MINARI R, ZECCA A, et al. Soluble PD-L1 and circulating CD8+PD-1+ and NK cells enclose a prognostic and predictive immune effector score in immunotherapy treated NSCLC patients [J].Lung Cancer, 2020, 148: 1-11.

相似文献/References:

[1]张 蕾,任亚女,曾婷婷,等.晚期非小细胞肺癌患者血液实验指标和病理分期等因素对生存时间的影响分析[J].现代检验医学杂志,2016,31(02):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
 ZHANG Lei,REN Ya-n,ZENG Ting-ting,et al.Analysis of Prognosis Related Factors in Patients with Advanced Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(01):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
[2]薛鸿涛,任 敏,李长彬.非小细胞肺癌患者放疗前后血清TSGF和CRP的变化及其临床意义[J].现代检验医学杂志,2016,31(02):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
 XUE Hong-tao,REN Min,LI Chang-bin.Impact and Clinical Significance of Radiotherapy on Serum TSGF and CRP in Patients with Non Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(01):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
[3]王京伟,李 艳,童永清,等.湖北地区非小细胞肺癌EGFR 基因突变及其意义的研究[J].现代检验医学杂志,2016,31(03):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
 WANG Jing-wei,LI Yan,TONG Yong-qing,et al.Detection of Epidermal Growth Factor Receptor(EGFR) Mutations and the Significance in Patients with Non-small Cell Lung Cancer(NSCLC)of Hubei Province[J].Journal of Modern Laboratory Medicine,2016,31(01):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
[4]易甲其,范艳平,周宁加,等.血清PTX-3,CYFRA21-1和TPS在非小细胞肺癌中的变化及临床意义[J].现代检验医学杂志,2015,30(05):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
 YI Jia-qi,FAN Yan-ping,ZHOU Ning-jia,et al.Changes and Clinical Significance of Serum PTX-3, CYFRA21-1,TPS in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2015,30(01):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
[5]钱忠萍,凌 晨,祁松楠,等.围非小细胞肺癌手术期T细胞含量变化的研究[J].现代检验医学杂志,2016,31(05):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
 QIAN Zhong-ping,LING Chen,QI Song-nan,et al.Content Variation of T Cells in Perioperative Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(01):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
[6]黎谢梦丹,罗 凯,吴顺芳,等.华南地区非小细胞肺癌患者肿瘤组织EGFR,ALK和ROS1基因突变分析[J].现代检验医学杂志,2017,32(05):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
 LIXIE Meng-dan,LUO Kai,WU Shun-fang,et al.Mutation Analysis of EGFR,ALK and ROS1 in Tumor Tissues of Patients with Non-Small Cell Lung Cancer in South of China[J].Journal of Modern Laboratory Medicine,2017,32(01):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
[7]李小龙,白巧艳,陆婉玲.老年非小细胞肺癌患者低分割放疗对凝血功能的影响[J].现代检验医学杂志,2018,33(05):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
 LI Xiao-long,BAI Qiao-yan,LU Wan-ling.Influence of Hypofractionated High-Dose Radiotherapy on Coagulation Function in Elderly Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(01):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
[8]郭 华a,齐宗利a,张海祥b,等.非小细胞肺癌组织EGFR/ALK/ROS1基因联合检测的临床意义[J].现代检验医学杂志,2018,33(06):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
 GUO Huaa,QI Zong-lia,ZHANG Hai-xiangb,et al.Clinical Significance of Combined Detection of EGFR/ALK/ROS1 Genes in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(01):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
[9]黄 刚,陈 霏,肇玉博,等.非小细胞肺癌患者血浆miRNA-145和miRNA-221表达与临床特征及术后复发的相关性研究[J].现代检验医学杂志,2019,34(04):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
 HUANG Gang,CHEN Fei,ZHAO Yu-bo,et al.Study on the Correlation between the Expression of MicroRNA145 and MicroRNA221 in Plasma and Clinical Characteristics and Postoperative Recurrence in Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2019,34(01):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
[10]蒋玲丽,黄中强,王雪亮,等.表皮生长因子受体(EGFR)基因突变检测质控品制备及应用[J].现代检验医学杂志,2020,35(02):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]
 JIANG Ling-li,HUANG Zhong-qiang,WANG Xue-liang,et al.Development and Application of Quality Control Materials for EpidermalGrowth Factor Receptor (EGFR)Mutation Determination[J].Journal of Modern Laboratory Medicine,2020,35(01):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]

备注/Memo

备注/Memo:
基金项目: 国家自然科学基金面上项目(82274595):基于巨噬细胞极化及Th1 细胞串扰探讨肺平方延缓肺癌耐药机制;上海市科学技术委员会科技计划项目(20Y21902000):益气养阴法联合EGFR-TKI 靶向治疗IV 期肺癌优势人群的前瞻性研究;上海市科学技术委员会“科技创新行动计划”自然科学基金项目(22ZR1462400):益气养阴解毒方调控MMP2/PD-L1 介导的免疫逃逸延缓EGFR-TKI 耐药的分子机制。
作者简介:田雪琪(1998-),女,硕士研究生在读,研究方向:中医药防治恶性肿瘤,E-mail:xqtian98@163.com。
通讯作者: 许玲(1967-),女,博士研究生,博士生导师,教授,主任医师,研究方向:中医药防治恶性肿瘤,E-mail:xulq67@aliyun.com。
更新日期/Last Update: 2024-01-15